Un-Audited Financial Results for the Quarter and Half year ended on 30th September 2025 along with Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenlabs Ethica, a pharmaceutical formulations trading company, reported a decline in both revenue and profits for Q2 FY26 and H1 FY26 compared to the same period last year. Revenue from operations fell to ₹1,243.34 lakhs in Q2 (from ₹1,335.15 lakhs) and to ₹2,391.06 lakhs in H1 (from ₹2,571.41 lakhs), a drop of around 7% year-on-year. Profit after tax declined to ₹3.76 lakhs in Q2 (from ₹5.17 lakhs) and ₹7.09 lakhs in H1 (from ₹9.35 lakhs), a drop of roughly 24-27%. Operating cash flow remained healthy at ₹346.36 lakhs for H1, and the company continued to reduce its borrowings. The statutory auditor N Kumar Chhabra and Co. issued an unmodified (clean) limited review report with no qualifications.
The results show top-line pressure and shrinking margins, with profits falling faster than revenue, which is a mild negative for the stock. However, the company remains profitable, has a clean auditor report, and is steadily paying down debt, which limits downside concern.